Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery

NCT04087096 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Bariatric Surgery Candidate
Bone Loss

Interventions

DRUG: Denosumab
DRUG: Placebo
DRUG: Zoledronic Acid

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]
[object Object]